Fosamax and Osteonecrosis of the Jaw: Risk, Causation, and What Studies Reveal

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Occupational Risk Assessment

The legacy context of general health and science information has long served as a foundation for public understanding of medical conditions and treatments. Within this broad domain, discussions of bone health and therapeutic interventions have been standard, with emphasis on maintaining skeletal integrity and managing age-related changes. This heritage provides a baseline for evaluating how specific pharmaceutical exposures may shift risk profiles in ways not fully captured by general health guidance. Transitioning from this general framework, the focus narrows to a particular occupational exposure concern: the relationship between Fosamax, a bisphosphonate medication, and the risk of osteonecrosis of the jaw. While general health information typically addresses population-level risks and benefits, occupational contexts demand scrutiny of sustained, high-level exposure scenarios. Workers in healthcare, pharmaceutical manufacturing, or dental fields may encounter Fosamax through handling, administration, or patient contact, raising questions about cumulative exposure effects. The pivot here is from a passive, informational stance—where the public learns about risks—to an active, occupational one, where exposure is a routine part of professional duties. This shift requires examining how workplace conditions alter the risk calculus, moving beyond general health advisories to consider specific exposure pathways and durations that are not typical for the general population.

Understanding Fosamax and Its Mechanism of Action

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its pharmacological action involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence. However, a recognized adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation of ONJ involves bone exposure in the oral cavity, often accompanied by pain, swelling, and infection. Diagnosis is typically based on clinical examination and imaging, with a focus on ruling out other causes of jaw necrosis, such as metastatic disease or radiation therapy.

Mechanistic Pathways Linking Fosamax to Osteonecrosis of the Jaw

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Bisphosphonates like Fosamax inhibit osteoclast activity, which reduces bone turnover. In the jaw, which has a high rate of bone remodeling, this suppression may impair the ability to repair microdamage and respond to local infections or dental procedures, leading to necrosis. Additionally, bisphosphonates may have anti-angiogenic effects, further compromising blood supply to the jawbone.

Risk Factors and Duration of Exposure

The risk of ONJ with Fosamax use is influenced by several factors. Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). A cohort study among female patients treated for osteoporosis in the United Kingdom found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use, though absolute risks remained low (approximately 0.05% after 5 years) and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/).

Timeline of Onset and Resolution of Symptoms

The timeline between exposure to Fosamax and documented harm varies. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Adequacy of Warnings and Clinical Management

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific warning under section 5.4 about osteonecrosis of the jaw, noting that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The warning also advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of Fosamax use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use is considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Causation considerations for affected patients involve assessing the temporal relationship between Fosamax exposure and ONJ onset, excluding other potential causes such as cancer or radiation therapy, and evaluating the presence of known risk factors. The evidence suggests a dose- and duration-dependent relationship, with higher risk after prolonged use. For patients who develop ONJ, management typically includes discontinuation of the bisphosphonate, conservative dental care, and treatment of any underlying infection. The risk diminishes after discontinuation, but patients should be monitored for recurrence if rechallenged with bisphosphonates.

Summary of Evidence and Implications

In summary, studies show that Fosamax use is associated with an increased risk of ONJ, particularly with longer duration of use and in the presence of risk factors such as invasive dental procedures. The prescribing information includes warnings about this risk, and patients should be counseled on maintaining good oral hygiene and avoiding elective dental procedures during treatment. The absolute risk remains low, but affected patients may experience significant morbidity.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that inhibits bone resorption. Studies show it increases the risk of osteonecrosis of the jaw (ONJ), especially with longer use and in patients undergoing invasive dental procedures. The risk is dose- and duration-dependent, with a threefold increase after 2-3 years and eightfold after 10 years (https://pubmed.ncbi.nlm.nih.gov/39400702/).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (e.g., tooth extraction, implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Duration of bisphosphonate use also increases risk.

How long does it take for ONJ symptoms to appear after starting Fosamax?

The time to onset of symptoms can range from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients improve after stopping the drug, but some may have recurrence if rechallenged.

Are there adequate warnings about ONJ in Fosamax prescribing information?

Yes, the prescribing information includes a specific warning (section 5.4) about osteonecrosis of the jaw, noting it has been reported with bisphosphonates including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). It advises that discontinuation before invasive dental procedures may reduce risk.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.